… PURPOSE: To compare four cycles of therapy versus continuous therapy to determine
the optimal duration of chemotherapy in advanced non–small-cell lung cancer (NSCLC). …

… therapy for patients with advanced non-small cell lung cancer. Non-small cell lung cancer
(NSCLC) is the leading cause of cancer mortality in industrialized countries. The current …

… , 146 patients with small cell carcinoma of the lung, staged as … among patients receiving
continuous therapy compared to … with advanced small cell lung cancer. Continuous regimen ( …

… of immunotherapy, including for non–small-cell lung cancer (NSCLC). We present an …
of 1-year fixed-duration versus continuous therapy on the efficacy and safety of nivolumab. …

… the continuous therapy, the magnitude of the increase is small, 3 months or less. Havermann
et al also reported an increase in 2-year survival from 3% to 6% in patients receiving the …

… A key challenge in the treatment of advanced non–small-cell lung cancer (NSCLC) is
improving outcomes for patients who have achieved at least stable disease after standard first-line …

… and not cross-resistant, (3) the application of additional treatment strategies such as
radiotherapy or surgery, and (4) the criteria and time for shifting patients from continuous therapy to …

… treatment modality in small cell lung cancer. This approach has … a period of initial common
continuous therapy. The results of … performed continuous therapy in small cell lung cancer. …

Treatment of lung cancer had evolved during the last decade with the introduction of new
chemotherapeutic regimens and targeted therapies. However, the maximum benefit reached …

… Lung cancer is the leading cause of cancer mortality in the United States, and it is estimated
… million deaths related to lung cancer worldwide.1, 2 Non-small cell lung cancer (NSCLC) …